Drug
Protease Inhibitor Formulation LB1148 clinical trials
How studies write it
Studies that test it under each name
Written with another drug
- LB1148
- 5
Studies by the year they started
5 studies that test it; most in 2019 (2)
| Year | Studies |
|---|---|
| 2015 | 1 |
| 2019 | 2 |
| 2021 | 1 |
| 2022 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 5 · Other 0
Palisade Bio (2) · Leading BioSciences, Inc (2) · Newsoara Biopharma Co., Ltd. (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses Protease Inhibitor Formulation LB1148 is read from its arms, and is right about nine times in ten.
Testing it · 5
- A Study to Evaluate LB1148 for Return of Gastrointestinal Function and Adhesions in Subjects Undergoing Bowel ResectionCompletedPhase 2Palisade BioNCT02836470Written as LB1148
- A Study to Evaluate LB1148 for Return of Bowel Function in Subjects Undergoing Bowel ResectionTerminatedPhase 3Palisade BioNCT05470387Written as LB1148
- LB1148 for Pulmonary Dysfunction Associated With COVID-19 PneumoniaWithdrawnPhase 2Leading BioSciences, IncNCT04390217Written as LB1148
- Study to Evaluate LB1148 for Return of Gastrointestinal Function, Decrease Post-Operative IleusCompletedPhase 2Newsoara Biopharma Co., Ltd.NCT05056935Written as LB1148
- Treatment of Septic Shock by Inhibiting Autodigestion and Preserving Gut Integrity With Enteric LB1148TerminatedPhase 2Leading BioSciences, IncNCT02317549Written as LB1148